All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-01-20T14:59:34.000Z

Imbruvica® (Ibrutinib) given FDA accelerated approval in the treatment of R/R MZL

Jan 20, 2017
Share:

Bookmark this article

This week the Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for use in Marginal Zone Lymphoma (MZL) patients. Imbruvica® is a Bruton’s Tyrosine Kinase (BTK) targeting therapy that already has approval in other lymphoma subtypes such as CLL and WM. The newly approved indication for Imbruvica® is in R/R MZL patients who require systemic therapy having already received at least one anti-CD20-based therapy, and marks the first approved treatment in relapsed/refractory MZL. The accelerated approval in MZL means the approval is conditional upon continued study results and further trial data.

The accelerated approval comes after the results of the PCYC-1121 trial (NCT01980628), which were reported by Ariela Noy during the American Society of Hematology Annual Meeting 2016, where the Lymphoma Hub interviewed Stefano Luminari on the oral presentation. The PCYC-1121 study of Imbruvica® treatment in 63 MZL patients reported an overall response rate of 46% (95% CI: 33.4–59.1), with 42.9% achieving partial recovery and 3.2% achieving complete recovery. 

  1. IMBRUVICA® (Ibrutinib) Approved by FDA For Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy. 2017 Jan 19.http://www.biospace.com/News/janssen-biotech-release-imbruvica-ibrutinib/444570. [Accessed 20/01/17].
  2. Noy A. et al. Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. 2016 December 5; Oral Abstract #1213: ASH 58th Annual Meeting and Exposition, San Diego, CA.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox